Classification and staging of retinoblastoma

Classifying and staging retinoblastoma is an essential first step when planning how to manage a child with the condition; it also gives important information about prognosis.

Classification schemes in cancer are mainly used to compare the results of different treatments and to enable a prognosis to be given.

Classification of extraocular disease

If retinoblastoma is left untreated, it will extend beyond the eye. Unfortunately, this is the type most commonly seen in low- and middle-income countries. The tumour can penetrate the globe wall and be visible in and around the eye. It can also reach the central nervous system via the optic nerve, or it can spread to other parts of the body via the blood stream (metastases).

In 2006, Chantada and colleagues developed the International Retinoblastoma Staging System (IRSS; Table 1).\(^1\) It sub-classifies the disease from stage 0–IV. Stage 0 is intraocular disease, usually having a good outcome with treatment, and stage IV is retinoblastoma with metastases, which has a poor prognosis.

Classification of intraocular disease

For intraocular retinoblastoma, the first classification system was introduced by Reese and Ellsworth (R-E) in the 1960s to predict the chances of saving the eye following external beam radiotherapy. When intravenous chemotherapy for intraocular retinoblastoma was introduced in the 1990s, the R–E classification system was no longer appropriate and a new classification scheme, the International Intraocular Retinoblastoma Classification (IIRC) scheme, was developed.\(^2\)

The IIRC scheme groups tumours from A–E, depending on their size, location, and additional features.

In 2006, Chantada and colleagues developed the International Retinoblastoma Staging System (IRSS; Table 1).\(^1\) It sub-classifies the disease from stage 0–IV. Stage 0 is intraocular disease, usually having a good outcome with treatment, and stage IV is retinoblastoma with metastases, which has a poor prognosis.

| Stage | Clinical Description |
|-------|----------------------|
| 0     | Patient treated conservatively |
| I     | Eye enucleated, completely resected histologically |
| II    | Eye enucleated, microscopic residual tumour |
| III   | Regional extension |
|      | a. Overt orbital disease |
|      | b. Preauricular or cervical lymph node extension |
| IV    | Metastatic disease |
|      | a. Haematogenous metastasis (without central nervous system involvement) |
|      | 1 Single lesion |
|      | 2 Multiple lesions |
|      | b. Central nervous system extension (with or without any other site of regional or metastatic disease) |
|      | 1 Prechiasmatic lesion |
|      | 2 Central nervous system mass |
|      | 3 Leptomeningeal and cerebrospinal fluid disease |

Table 1 International Retinoblastoma Staging System (IRSS)
including the presence of retinoblastoma ‘seeds’ (small colonies of cancerous cells in the vitreous) and/or retinal detachment. Shields and colleagues developed a modified scheme, the Intraocular Classification of Retinoblastoma (ICRB), which differed from the IIRC mainly in the definitions of the advanced groups, D and E. In 2006, the ICRB scheme was found to successfully predict the outcome of intravenous chemotherapy.3

- For eyes in groups A–C: the globe could be salvaged in ≥90% of eyes.
- For eyes in group D: the globe could be salvaged in 47% of eyes.
- Group E eyes underwent primary enucleation and were excluded from analysis.

Both the IIRC and ICRB classification systems (see Table 2, overleaf) are now used as the main classification schemes for intraocular retinoblastoma and serve clinicians and researchers across the world.4 The images in Figure 1 correspond to each category.

Intravenous chemotherapy was found to be effective in treating tumours confined to the retina; however, vitreous seeds seemed to be resistant to the treatment. In 2012,
Munier and colleagues developed a technique for injecting chemotherapy directly into the vitreous cavity. They used a classification system that grouped retinoblastoma seeds, based on their morphology and size, as dust, spheres and clouds. Since the introduction of the intravitreal technique, the classification of vitreous seeds is now commonly used to predict the number of injections needed to control the various seed types.

Another classification system that is used for all cancer types, including retinoblastoma, was created by the American Joint Committee on Cancer (AJCC). The TNM scheme classifies cancer according to involvement of the primary site: tumour (T), lymph nodes (N) and presence of systemic metastasis (M). The recently published 8th edition includes a hereditary (H) component for Rb, making it the cTNMH scheme (c for clinical). The cTNMH categories are based on whether the tumour burden is determined to be intraretinal, intraocular, advanced intraocular or extracocular. The TNM scheme also has a pathological (pTNM) sub-classification which is widely used by ophthalmic pathologists. Read this article online to see the full scheme: www.cehjournal.org.

**Summary**

Classification and staging systems for retinoblastoma have evolved as new treatments became available. Several schemes are currently available. For disease confined to the globe, the IIRC, ICRB and cTNMH systems are available, along with additional classifications describing vitreous seeds. For extracocular disease, the IRSS and cTNMH schemes can be used.

### Table 2: Classification systems for Intraocular Retinoblastoma

| International Intraocular Retinoblastoma Classification (IIRC) | Intraocular Classification of Retinoblastoma (ICRB) |
|---------------------------------------------------------------|-------------------------------------------------|
| **Group A (very low risk)**                                  | Retinoblastoma ≤ 3 mm (in basal dimension or thickness) |
| All tumours are 3 mm or smaller, confined to the retina and at least 3 mm from the foveola and 1.5 mm from the optic nerve. No vitreous or subretinal seeding is allowed | |
| **Group B (low risk)**                                       | Retinoblastoma > 3 mm (in basal dimension or thickness) or |
| Eyes with no vitreous or subretinal seeding and discrete retinal tumour of any size or location. Retinal tumours may be of any size or location not in group A. Small cuff of subretinal fluid extending ≤5 mm from the base of the tumour is allowed | • Macular location (≤3 mm from foveola) |
| **Group C (moderate risk)**                                  | • Juxtapapillary location (≤1.5 mm to disc) |
| Eyes with focal vitreous or subretinal seeding and discrete retinal tumours of any size and location. Any seeding must be local, fine, and limited so as to be theoretically treatable with a radioactive plaque. Up to one quadrant of subretinal fluid may be present | • Additional subretinal fluid (≤3 mm from margin) |
| **Group D (high risk)**                                      | Retinoblastoma with: |
| Eyes with diffuse vitreous or subretinal seeding and/or massive, non-discrete endophytic or exophytic disease | • Subretinal seeds ≤ 3 mm from tumour |
| Eyes with more extensive seeding than Group C Massive and/or diffuse intraocular disseminated disease including exophytic disease and >1 quadrant of retinal detachment. May consist of ‘greasy’ vitreous seeding or avascular masses. Subretinal seeding may be plaque-like | • Vitreous seeds ≤ 3 mm from tumour |
| **Group E (very high risk)**                                 | • Both subretinal and vitreous seeds ≤ 3 mm from tumour |
| Eyes that have been destroyed anatomically or functionally with one or more of the following: Irreversible neovascular glaucoma, massive intraocular haemorrhage, aseptic orbital cellulitis, tumour anterior to anterior vitreous face, tumour touching the lens, diffuse infiltrating retinoblastoma and phthisis or pre-phthisis | Retinoblastoma with: |
| • Extensive retinoblastoma occupying >50% globe or with | • Subretinal seeds > 3 mm from tumour |
| • Neovascular glaucoma | • Vitreous seeds > 3 mm from tumour |
| • Opaque media from haemorrhage in anterior chamber, vitreous or subretinal space | • Both subretinal and vitreous seeds > 3 mm from retinoblastoma |

### References

1. Chantada G, Dou F, Antoniou CM, Grundy R, Clare Stanward FF, Dunkel IJ et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Ca 2000;47:801-805
2. Linn Murphee A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2018;14:41–53.
3. Shields CL, Mashayekhi A, Au AK, et al: The International Classification of Retinoblastoma Predicts Chemoreduction Success. Ophthalmology 2006;113:2276–2280.
4. Scelfo C, Francis JH, Khetan V, Jenkiens T, Marr B, Abramson DH et al. An international survey of classification and treatment choices for group D retinoblastoma. Int J Ophthalmol 2017;10(6):961-967
5. Munier FL, Gaillard MC, Balme A, Soliman S, Podinsky G, Moulin AP, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 2012;96:1078–1083.
6. Berry JL, Schodt M, Shah S, Zolfaghari E, Reid M, Jabran R, Kim JW. Not all seeds are created equal: seed classification is predictive of outcomes in retinoblastoma. Ophthalmology 2017;124:1817–1825.
7. Mallapatia AC, Gallie BL, Chévez-Barrionuevo P, Lumbroso-Le Roux L, Chantada G, Dou F, Munier FL, et al: In: Amin MB, Edge SB, Greer RL, et al., eds: AJCC Cancer Staging Manual. 8th ed. New York: Springer, 2017.